Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib + Corticosteroids in First-Line Acute GVHD
NCT04220632Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Jun 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of itacitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Innovent Biologics. Primary endpoint: Overall response rate at 28 days. Started Jun 2020; status: terminated.
02
Drugs
itacitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04220632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220632.